Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 125
Filter
1.
Metabolism ; 102: 153963, 2020 01.
Article in English | MEDLINE | ID: mdl-31593706

ABSTRACT

BACKGROUND: Pregnancy represents a major metabolic challenge for the mother, and involves a compensatory response of the pancreatic beta-cell to maintain normoglycemia. However, although pancreatic alpha-cells play a key role in glucose homeostasis and seem to be involved in gestational diabetes, there is no information about their potential adaptations or changes during pregnancy. MATERIAL AND METHODS: Non-pregnant (controls) and pregnant C57BL/6 mice at gestational day 18.5 (G18.5) and their isolated pancreatic islets were used for in vivo and ex vivo studies, respectively. The effect of pregnancy hormones was tested in glucagon-secreting α-TC1.9 cells. Immunohistochemical analysis was performed in pancreatic slices. Glucagon gene expression was monitored by RT-qPCR. Glucagon secretion and plasma hormones were measured by ELISA. RESULTS: Pregnant mice on G18.5 exhibited alpha-cell hypertrophy as well as augmented alpha-cell area and mass. This alpha-cell mass expansion was mainly due to increased proliferation. No changes in alpha-cell apoptosis, ductal neogenesis, or alpha-to-beta transdifferentiation were found compared with controls. Pregnant mice on G18.5 exhibited hypoglucagonemia. Additionally, in vitro glucagon secretion at low glucose levels was decreased in isolated islets from pregnant animals. Glucagon content was also reduced. Experiments in α-TC1.9 cells indicated that, unlike estradiol and progesterone, placental lactogens and prolactin stimulated alpha-cell proliferation. Placental lactogens, prolactin and estradiol also inhibited glucagon release from α-TC1.9 cells at low glucose levels. CONCLUSIONS: The pancreatic alpha-cell in mice undergoes several morphofunctional changes during late pregnancy, which may contribute to proper glucose homeostasis. Gestational hormones are likely involved in these processes.


Subject(s)
Adaptation, Physiological/physiology , Gestational Age , Glucagon-Secreting Cells/cytology , Glucagon-Secreting Cells/physiology , Animals , Cell Count , Cell Size , Cells, Cultured , Female , Glucagon/metabolism , Islets of Langerhans/cytology , Islets of Langerhans/physiology , Mice , Mice, Inbred C57BL , Placental Hormones/physiology , Pregnancy
2.
In. Hernández Yero, José Arturo. Trastornos hipofisarios y gestación. La Habana, Editorial Ciencias Médicas, 2019. , ilus, tab.
Monography in Spanish | CUMED | ID: cum-74138
3.
Chest ; 153(4): 1052-1066, 2018 04.
Article in English | MEDLINE | ID: mdl-29066388

ABSTRACT

Emerging literature suggests that sleep-disordered breathing (SDB) worsens over the course of pregnancy and is associated with adverse maternal and fetal outcomes. Earlier studies, using mainly snoring as a surrogate marker for SDB, have shown an increase in the prevalence of SDB during pregnancy compared with that in the pregravid state. More recently, prospective observational studies in which the investigators ascertained SDB by using complete polysomnography have shown a prevalence ranging from approximately 17% to 45% in the third trimester. Pregnancy itself can be associated with daytime hypersomnolence, so complaints of increasing fatigue and sleepiness during pregnancy are not specific for SDB. Moreover, snoring in isolation also has relatively poor sensitivity and specificity as a screening tool for diagnosing maternal SDB. The indications for screening for SDB during routine obstetric prenatal visits are still unclear, but observational studies indicate that maternal SDB is linked with the development of adverse pregnancy outcomes, such as gestational hypertension and gestational diabetes mellitus. Some studies also have identified a relationship between maternal SDB and the delivery of infants who are small for gestational age. Aside from a few small interventional studies of CPAP in pregnant patients with gestational hypertension, little currently is known about whether treatment of SDB during pregnancy improves clinical outcomes for the mother and/or baby. Additional current knowledge gaps include elucidating underlying mechanisms of maternal SDB, determining optimal treatment strategies, and understanding the trajectory of SDB after delivery.


Subject(s)
Pregnancy Complications/therapy , Sleep Apnea Syndromes/therapy , Blood Glucose/metabolism , Continuous Positive Airway Pressure , Diabetes, Gestational/diagnosis , Diabetes, Gestational/etiology , Diabetes, Gestational/therapy , Early Diagnosis , Female , Humans , Hypertension, Pregnancy-Induced/diagnosis , Hypertension, Pregnancy-Induced/etiology , Hypertension, Pregnancy-Induced/therapy , Placental Hormones/metabolism , Placental Hormones/physiology , Polysomnography , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Complications/etiology , Pregnancy Outcome , Prenatal Care/methods , Prenatal Diagnosis/methods , Risk Factors , Sleep Apnea Syndromes/diagnosis , Sleep Apnea Syndromes/etiology , Surveys and Questionnaires
5.
Placenta ; 36 Suppl 1: S50-9, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25524059

ABSTRACT

Hormones have an important role in regulating fetal development. They act as environmental signals and integrate tissue growth and differentiation with relation to nutrient availability. While hormones control the developmental fate of resources available to the fetus, the actual supply of nutrients and oxygen to the fetus depends on the placenta. However, much less is known about the role of hormones in regulating placental development, even though the placenta has a wide range of hormone receptors and produces hormones itself from early in gestation. The placenta is, therefore, exposed to hormones by autocrine, paracrine and endocrine mechanisms throughout its lifespan. It is known to adapt its phenotype in response to environmental cues and fetal demand signals, particularly when there is a disparity between the fetal genetic drive for growth and the nutrient supply. These adaptive responses help to maintain fetal growth during adverse conditions and are likely to depend, at least in part, on the hormonal milieu. This review examines the endocrine regulation of placental phenotype with particular emphasis on the glucocorticoid hormones. It focuses on the availability of placental hormone receptors and on the effects of hormones on the morphology, transport capacity and endocrine function of the placenta.


Subject(s)
Hormones/pharmacology , Placenta/drug effects , Placentation/drug effects , Animals , Female , Fetal Development/drug effects , Hormones/physiology , Humans , Maternal-Fetal Exchange/drug effects , Phenotype , Placenta/physiology , Placental Hormones/pharmacology , Placental Hormones/physiology , Pregnancy , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, Cytoplasmic and Nuclear/physiology
6.
Neuropeptides ; 47(6): 363-70, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24210135

ABSTRACT

Postpartum depression affects 10-20% of women following birth and exerts persisting adverse consequences on both mother and child. An incomplete understanding of its etiology constitutes a barrier to early identification and treatment. It is likely that prenatal hormone trajectories represent both markers of risk and also causal factors in the development of postpartum depression. During pregnancy the maternal hypothalamic-pituitary-adrenal axis undergoes dramatic alterations, due in large part, to the introduction of the placenta, a transient endocrine organ of fetal origin. We suggest that prenatal placental and hypothalamic-pituitary-adrenal axis dysregulation is predictive of risk for postpartum depression. In this model the positive feedback loop involving the systems regulating the products of the HPA axis results in higher prenatal levels of cortisol and placental corticotropin-releasing hormone. Greater elevations in placental corticotropin-releasing hormone are related to a disturbance in the sensitivity of the anterior pituitary to cortisol and also perhaps to decreased central corticotropin-releasing hormone secretion. Secondary or tertiary adrenal insufficiencies of a more extreme nature, which emerge during the prenatal period, may be predictive of an extended or more pronounced postpartum hypothalamic-pituitary-adrenal refractory period, which in turn represents a risk factor for development of postpartum depression. In addition to reviewing the relevant existing literature, new data are presented in support of this model which link elevated placental corticotropin-releasing hormone with low levels of ACTH at 3-months postpartum. Future research will further elucidate the role of hypothalamic-pituitary-adrenal axis dysregulation in postpartum depression and also whether prenatal placental and hypothalamic-pituitary-adrenal profiles might prove useful in the early identification of mothers at risk for postpartum mood dysregulation.


Subject(s)
Depression, Postpartum/physiopathology , Depressive Disorder, Major/physiopathology , Hypothalamo-Hypophyseal System/physiopathology , Pituitary-Adrenal System/physiopathology , Adrenal Cortex Hormones/physiology , Female , Humans , Hypothalamic Hormones/physiology , Placenta/physiology , Placental Hormones/physiology , Pregnancy , Risk Factors , Stress, Physiological
7.
Growth Horm IGF Res ; 23(1-2): 13-8, 2013.
Article in English | MEDLINE | ID: mdl-23206731

ABSTRACT

BACKGROUND: High homology of GH with placental GH (pGH) and hPL frequently resulted in falsely high GH levels in competitive immunoassays during pregnancy. However, in immunometric assays, falsely high or low GH levels can result from GH-like molecules binding to both or only one monoclonal antibody. Since our GH-IFMA assay detected GH suppression in both normal and acromegalic pregnancies, we evaluated potential negative interference of pregnancy serum in the assay. METHODS: GH was measured in samples from acromegalic patients with and without the addition of normal pregnancy serum using a sensitive in-house two-step GH-IFMA (no crossreactivity with pGH, Prolactin or hPL). Standard GH assay curves were run with and without pGH (20 and 22 K). Pegvisomant, a GH-antagonist with high homology to GH, was also tested for cross-reactivity. RESULTS: Addition of pregnancy serum to acromegaly serum resulted in marked decrease in GH, but addition of pGH did not change GH measurements. Redesign of the routine assay by switching the positions of the antibodies ("inverted" assay) completely abrogated the interference of pregnancy serum. GH by both routine and inverted assays declined progressively throughout pregnancy in controls, with higher nadir levels in the "inverted" assay (median 0.03 µg/L vs 0.50 µg/L, P<0.05). GH suppression during acromegalic pregnancy previously found with the routine assay was not observed in the "inverted" assay. Pegvisomant does not cross-react with GH in the "inverted" assay. CONCLUSIONS: GH measurements in pregnancy by immunometric assays must be made after exclusion of pregnancy serum interference by dilutional tests. Redesigning a two-step immunometric GH assay by switching the positions of the antibodies can be a successful strategy to abrogate such interference.


Subject(s)
Acromegaly/blood , Acromegaly/diagnosis , Human Growth Hormone/blood , Placenta/metabolism , Placental Hormones/blood , Pregnancy/blood , Acromegaly/metabolism , Animals , Case-Control Studies , Cells, Cultured , Cross Reactions , False Positive Reactions , Female , Human Growth Hormone/analysis , Human Growth Hormone/metabolism , Humans , Immunoassay/methods , Mice , Mice, Inbred BALB C , Placenta/physiology , Placental Hormones/metabolism , Placental Hormones/physiology , Pregnancy/metabolism , Pregnancy Complications/blood , Pregnancy Complications/diagnosis , Pregnancy Complications/metabolism
8.
Breast Cancer Res Treat ; 137(1): 237-46, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23135573

ABSTRACT

Breast cancer incidence rates have declined among older but not younger women; the latter are more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as much as 10 years post-partum. We investigated the association between years since last full-term pregnancy at the time of diagnosis (≤10 or >10 years) and breast tumor subtype in a case series of premenopausal Hispanic women (n = 627). Participants were recruited in the United States, Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and HER2 status, with one or more full-term pregnancies ≥1 year prior to diagnosis were eligible for this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+ = ER+ and/or PR+; HR- = ER- and PR-) expression and HER2 status: HR+/HER2-, HER2+ (regardless of HR), and triple negative breast cancer. Case-only odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2- tumors. Participants were pooled in a mixed-effects logistic regression model with years since pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2- cases, women with HER2+ tumors were more likely be diagnosed in the post-partum period of ≤10 years (OR = 1.68; 95 % CI, 1.12-2.52). The effect was present across all source populations and independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (≤45 or >45 years) did not materially alter our results (OR = 1.78; 95 % CI, 1.08-2.93). These findings support the novel hypothesis that factors associated with the post-partum breast, possibly hormonal, are involved in the development of HER2+ tumors.


Subject(s)
Breast Neoplasms/metabolism , Receptor, ErbB-2/metabolism , Adult , Breast Neoplasms/epidemiology , Female , Gonadal Steroid Hormones/physiology , Hispanic or Latino , Humans , Incidence , Logistic Models , Mexico/epidemiology , Middle Aged , Placental Hormones/physiology , Pregnancy , Premenopause , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Spain/epidemiology , United States/epidemiology , Young Adult
9.
Placenta ; 33 Suppl 2: e11-5, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22652046

ABSTRACT

Pregnancy is generally a co-operative interaction between mother and fetus in which the evolutionary genetic interests of both benefit from production of healthy offspring. While this view is largely supported by empirical data, Kinship Theory predicts that mother and fetus will disagree over the optimum level of maternal investment that maximises their respective fitnesses. This conflict will be more evident with polyandrous than monogamous mating systems, when resources are scarce and in late gestation when the fetus is growing maximally, particularly if conceptus mass is large relative to maternal mass. As the site of nutrient transfer, the placenta is pivotal in the tug-of-war between mother and fetus over resource allocation. It responds to both fetal signals of nutrient demand and maternal signals of nutrient availability and, by adapting its phenotype, regulates the distribution of available resources. These adaptations involve changes in placental size, morphology, transport characteristics, metabolism and hormone bioavailability. They are mediated by key growth regulatory, endocrine and nutrient supply genes responsive to mismatches between nutrient availability and the fetal genetic drive for growth. Indeed, evolution of genomic imprinting and placental secretion of hormones are believed to have been driven by maternal-fetal conflict over resource allocation. Although many of the specific mechanisms involved still have to be identified, the placenta confers optimal fitness on the offspring for its developmental environment by balancing conflict and cooperation in the allocation of resources through generation of nutrient transport phenotypes specific to the prevailing nutritional conditions and/or fetal genotype.


Subject(s)
Maternal-Fetal Exchange , Placenta/physiology , Prenatal Nutritional Physiological Phenomena , Animals , Female , Fetal Development/physiology , Genomic Imprinting , Humans , Placental Hormones/physiology , Pregnancy
10.
Curr Opin Endocrinol Diabetes Obes ; 18(6): 409-16, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21986512

ABSTRACT

PURPOSE OF REVIEW: To examine the roles of the placental and pituitary hormones in the control of maternal metabolism and fetal growth. RECENT FINDINGS: In addition to promoting growth of maternal tissues, placental growth hormone (GH-V) induces maternal insulin resistance and thereby facilitates the mobilization of maternal nutrients for fetal growth. Human placental lactogen (hPL) and prolactin increase maternal food intake by induction of central leptin resistance and promote maternal beta-cell expansion and insulin production to defend against the development of gestational diabetes mellitus. The effects of the lactogens are mediated by diverse signaling pathways and are potentiated by glucose. Pathologic conditions of pregnancy are associated with dysregulation of GH-V and hPL gene expression. SUMMARY: The somatogenic and lactogenic hormones of the placenta and maternal pituitary gland integrate the metabolic adaptations of pregnancy with the demands of fetal and neonatal development. Dysregulation of placental growth hormone and/or placental lactogen in pathologic conditions of pregnancy may adversely impact fetal growth and postnatal metabolic function.


Subject(s)
Fetus/physiology , Placenta/metabolism , Placental Hormones/physiology , Adipokines/metabolism , Female , Fetal Development/physiology , Glucocorticoids/metabolism , Humans , Insulin/metabolism , Leptin/metabolism , Maternal-Fetal Exchange/physiology , Pituitary Gland/metabolism , Placenta/chemistry , Pregnancy
12.
Circulation ; 120(24): 2470-7, 2009 Dec 15.
Article in English | MEDLINE | ID: mdl-19948974

ABSTRACT

BACKGROUND: Renal dysfunction is commonly accompanied by a worsening of atherosclerosis; however, the underlying molecular mechanism is not fully understood. We examined the role played by soluble fms-like tyrosine kinase-1 (sFlt-1), an endogenous antagonist of the proatherogenic cytokine placental growth factor (PlGF), in the worsening of atherosclerosis in patients with renal dysfunction and in an animal model of renal failure. METHODS AND RESULTS: In this study, 329 patients who received cardiac catheterization and 76 patients who underwent renal biopsy were enrolled. Both plasma sFlt-1 levels and renal sFlt-1 mRNA expression were positively correlated with estimated glomerular filtration rate (P<0.01). The PlGF/sFlt-1 ratio was negatively correlated with estimated glomerular filtration rate (P<0.01), whereas plasma PlGF levels were not affected by it. The PlGF/sFlt-1 ratio was significantly higher in patients with multivessel coronary artery disease than in patients with single-vessel or no coronary artery disease. The reduction of circulating sFlt-1 and renal sFlt-1 mRNA levels was confirmed in five-sixths (5/6)-nephrectomized apolipoprotein E-deficient mice that developed experimental renal dysfunction. Atherosclerotic plaque area and macrophage infiltration into the plaque were significantly higher in 5/6-nephrectomized apolipoprotein E-deficient mice than in control mice, but replacement therapy with recombinant sFlt-1 significantly reduced both plaque formation and macrophage infiltration. CONCLUSIONS: The present study demonstrates that a reduction in the circulating levels of sFlt-1 is associated with the worsening of atherosclerosis that accompanies renal dysfunction.


Subject(s)
Atherosclerosis/enzymology , Disease Models, Animal , Kidney Failure, Chronic/enzymology , Vascular Endothelial Growth Factor Receptor-1/blood , Vascular Endothelial Growth Factor Receptor-1/physiology , Adult , Aged , Animals , Apolipoproteins E/deficiency , Atherosclerosis/etiology , Atherosclerosis/physiopathology , Female , Growth Hormone/antagonists & inhibitors , Growth Hormone/blood , Growth Hormone/physiology , Humans , Kidney Failure, Chronic/genetics , Kidney Failure, Chronic/physiopathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Nephrectomy , Placental Hormones/antagonists & inhibitors , Placental Hormones/blood , Placental Hormones/physiology , Random Allocation , Vascular Endothelial Growth Factor Receptor-1/antagonists & inhibitors
13.
J Pineal Res ; 44(3): 335-40, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18339129

ABSTRACT

We investigated how maternal melatonin is regulated in pregnant rats. To examine the involvement of the conceptus (fetus and placenta) in serum melatonin concentrations, the number of conceptuses was experimentally reduced to one on day 7 of pregnancy (1-conceptus group). Maternal circulating nighttime melatonin levels increased toward day 21 of pregnancy and rapidly decreased to the non-pregnancy levels after parturition, whereas the maternal serum nighttime melatonin levels of the 1-conceptus group on day 21 of pregnancy were significantly lower than normal pregnancy bearing dams more than 10 conceptuses. When the fetuses were removed by fetectomy (all fetuses but not the placentae) on day 12 of pregnancy, serum melatonin concentrations were not decreased. To examine the source of circulating maternal melatonin, mRNA expression of N-acetyltransferase (NAT), which is a late limiting enzyme for melatonin synthesis, was examined in the placenta and fetal pineal. NAT was not expressed in the placenta and was negligible in the pineal gland of the fetus compared with the mother's pineal gland. To examine the effect of placental hormones on maternal melatonin production, a conditioned medium, which was made by incubating placenta of day 20 of pregnancy with medium, was injected into the 1-conceptus dams from day 17 to day 20 of pregnancy. Injection of conditioned medium significantly increased serum melatonin concentrations compared with the control values whereas charcoal treatment abolished the stimulatory effect of conditioned medium. In conclusion, maternal circulating melatonin is from the maternal pineal gland and is increased by placental hormones during pregnancy.


Subject(s)
Fetus/physiology , Melatonin/blood , Placenta/physiology , Pregnancy, Animal/physiology , Animals , Arylalkylamine N-Acetyltransferase/metabolism , Circadian Rhythm , Female , Placental Hormones/physiology , Pregnancy , Rats , Rats, Sprague-Dawley
14.
Placenta ; 29 Suppl A: S36-41, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17981323

ABSTRACT

The placentas of ruminants and muroid rodents express prolactin (PRL)-related genes whereas the placentas of anthropoid primates express growth hormone (GH)-related genes. The evolution of placental expression is associated with accelerated evolution of the corresponding pituitary hormone and destabilization of conserved endocrine systems. In particular, placental hormones often evolve novel interactions with new receptors. The adaptive functions of some placental hormones may be revealed only under conditions of physiological stress.


Subject(s)
Endocrine System/physiology , Growth Hormone/physiology , Placenta/physiology , Placental Hormones/physiology , Prolactin/physiology , Animals , Female , Humans , Pregnancy
15.
J Reprod Med ; 52(4): 313-6, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17506372

ABSTRACT

OBJECTIVE: To investigate the relation between arterial resistance and placental growth hormone (hGH-V) levels in the maternal circulation. STUDY DESIGN: Sixty-seven women with normal pregnancy, 13 with preeclampsia (PE) and 11 with intrauterine fetal growth restriction (IUGR) underwent Doppler sonography of the placental and nonplacental uterine and cubital artery and blood sampling. hGH-V was measured with a highly sensitive sandwich-type immunofluorometric assay and pituitary growth hormone (hGH-N) and insulinlike growth factor I (IGF-I) with a chemiluminescence assay. A p value of < 0.05 was considered significant. RESULTS: During normal pregnancy the arterial pulsatility index (PI) decreased (p < 0.001), serum levels of hGH-V and IGF-I increased (p < 0.0001), and hGH-N decreased (p < 0.0001). Pathologic pregnancies (PE, IUGR) showed a significant higher PI in all arteries, but hGH-V and the IGF-I were decreased. CONCLUSION: Our data demonstrate a strong correlation between decreasing uterine and peripheral arterial resistance and increasing hGH-V during normal pregnancies with impaired uterine blood flow there were lowered serum levels of hGH-V, hGH-N and IGF-I. Lower levels of hGH-V and hGH-N might contribute to impaired uteroplacental circulation.


Subject(s)
Fetal Growth Retardation/blood , Growth Hormone/physiology , Placenta/blood supply , Placental Hormones/physiology , Pre-Eclampsia/blood , Pregnancy/blood , Uterus/blood supply , Vascular Resistance , Adult , Arteries , Case-Control Studies , Female , Fetal Growth Retardation/physiopathology , Growth Hormone/blood , Humans , Insulin-Like Growth Factor I/metabolism , Placental Circulation , Pre-Eclampsia/physiopathology , Regional Blood Flow , Ultrasonography, Doppler, Pulsed/methods
16.
J Matern Fetal Neonatal Med ; 19(3): 125-33, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16690504

ABSTRACT

Pregnancy is a unique condition in which the conceptus is allowed to implant, survive, develop, and reach a considerable organ growth and maturation within the maternal body despite the fact that it is half genetically different from the mother. Moreover, it deeply influences the overall endocrine, metabolic, and immunological functions of the recipient mother. These objectives are accomplished through the establishment of several communication systems in which a large array of substances produced by the feto-placental unit reach specific maternal target organs and/or systems and modulate their function. The myometrium is a fundamental reproductive tissue involved in pregnancy maintenance as well as in labor onset and progression and is a potential target organ for such a communication system. An appropriate regulation of myometrial function is a key condition required for pregnancy to develop physiologically until full term is reached and for labor to start. Emerging experimental and clinical evidence suggests that a very complex feto-placental biomolecular communication system exists with the myometrium and is actively operative in the control of myometrial contractility in pregnancy and parturition through the production of a continuously increasing number of substances with endocrine, paracrine, and immunoregulatory actions.


Subject(s)
Maternal-Fetal Exchange/physiology , Myometrium/physiology , Parturition/physiology , Female , Hormones/physiology , Humans , Inflammation Mediators/physiology , Models, Biological , Placental Hormones/physiology , Pregnancy
17.
Horm Res ; 65 Suppl 3: 41-9, 2006.
Article in English | MEDLINE | ID: mdl-16612113

ABSTRACT

This review outlines the regulation of maternal metabolism by hormones, cytokines and growth factors, highlighting recent studies that implicate disordered somatolactogen signalling in the pathogenesis of perinatal growth failure and the development of the metabolic syndrome.


Subject(s)
Fetal Development/physiology , Pituitary Hormones/physiology , Placental Hormones/physiology , Pregnancy/metabolism , Animals , Female , Growth Hormone/physiology , Humans , Placental Lactogen/physiology , Prolactin/physiology
18.
Methods Mol Med ; 122: 355-65, 2006.
Article in English | MEDLINE | ID: mdl-16511993

ABSTRACT

Placental hormones contribute to changes in maternal physiology, especially to changes in the blood system. Methods are described to express a placental hormone from a cloned cDNA by transfection into a mammalian cell line, to purify the hormone, and to assess the activities of the hormone in primary mouse bone marrow cell cultures. The example used in this chapter is prolactin-like protein F (PLP-F), a recently discovered mouse placental hormone that acts on the myeloid lineage. This hormone has been expressed at high levels in stably transfected Chinese hamster ovary cells. The protein is secreted from these cells after cleavage of the signal sequence and the addition of N-linked carbohydrate. A series of chromatographic steps are used to purify the protein to homogeneity, which is verified by gel electrophoresis and silver staining; the identity of the purified protein is confirmed by immunoblot analysis. Purified protein is then assayed by addition to primary bone marrow cells and scoring the growth and the differentiation of the megakaryocyte progenitor, colony forming unit-megakaryocyte.


Subject(s)
Hematopoiesis/physiology , Placental Hormones/biosynthesis , Pregnancy Proteins/biosynthesis , Recombinant Proteins/biosynthesis , Animals , CHO Cells , Chromatography/methods , Colony-Forming Units Assay/methods , Cricetinae , Female , Genetic Vectors , Megakaryocytes/drug effects , Mice , Placenta/metabolism , Placental Hormones/isolation & purification , Placental Hormones/physiology , Plasmids , Pregnancy , Pregnancy Proteins/isolation & purification , Pregnancy Proteins/physiology , Recombinant Proteins/isolation & purification , Transfection/methods
19.
Biol Reprod ; 74(5): 913-22, 2006 May.
Article in English | MEDLINE | ID: mdl-16452456

ABSTRACT

Stanniocalcin (STC) is a hormone in fish that regulates calcium levels. Mammals have two orthologs of STC with roles in calcium and phosphate metabolism and perhaps cell differentiation. In the kidney and gut, STC regulates calcium and phosphate homeostasis. In the mouse uterus, Stc1 increases in the mesometrial decidua during implantation. These studies determined the effects of pregnancy and related hormones on STC expression in the ovine uterus. In Days 10-16 cyclic and pregnant ewes, STC1 mRNA was not detected in the uterus. Intriguingly, STC1 mRNA appeared on Day 18 of pregnancy, specifically in the endometrial glands, increased from Day 18 to Day 80, and remained abundant to Day 120 of gestation. STC1 mRNA was not detected in the placenta, whereas STC2 mRNA was detected at low abundance in conceptus trophectoderm and endometrial glands during later pregnancy. Immunoreactive STC1 protein was detected predominantly in the endometrial glands after Day 16 of pregnancy and in areolae that transport uterine gland secretions across the placenta. In ovariectomized ewes, long-term progesterone therapy induced STC1 mRNA. Although interferon tau had no effect on endometrial STC1, intrauterine infusions of ovine placental lactogen (PL) increased endometrial gland STC1 mRNA abundance in progestinized ewes. These studies demonstrate that STC1 is induced by progesterone and increased by a placental hormone (PL) in endometrial glands of the ovine uterus during conceptus (embryo/fetus and extraembryonic membranes) implantation and placentation. Western blot analyses revealed the presence of a 25-kDa STC1 protein in the endometrium, uterine luminal fluid, and allantoic fluid. The data suggest that STC1 secreted by the endometrial glands is transported into the fetal circulation and allantoic fluid, where it is hypothesized to regulate growth and differentiation of the fetus and placenta, by placental areolae.


Subject(s)
Calcium/metabolism , Endometrium/metabolism , Glycoproteins/metabolism , Placental Hormones/physiology , Progesterone/physiology , Animals , Blotting, Western , Female , Fetal Development , Fetus/metabolism , Growth Hormone/physiology , Immunohistochemistry , Male , Placentation , Pregnancy , RNA, Messenger/metabolism , Sheep , Uterus/metabolism
20.
Anim Reprod Sci ; 82-83: 551-66, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15271479

ABSTRACT

Production of growth promoting substances by the placenta is regulated differently from the way production of similar compounds is regulated by maternal organs in various cases. Gene duplication is one of the mechanisms that facilitated the evolution of placental specific endocrine activity. Cattle, sheep and goats, although evolutionarily related, differ significantly from each other in the way their placental growth hormone (GH) and prolactin (PRL)-like hormones have evolved. Cattle carry one copy of the GH gene and there is no evidence yet for expression of that single GH gene copy in the placenta. On the other hand, the ovine GH gene has been duplicated and both oGH copies are expressed in the placenta during early stages of gestation. Prolactin gene duplication in ruminants resulted in the formation of specific placental-expressed prolactin-related genes including the placental lactogen (PL) gene. In homologous state, ovine PL manifests PRL activity, but antagonizes GH activity. Ovine PL activity which can be mediated by PRL receptors or by hetero-dimerization of GH and PRL receptors, provide a novel regulatory mechanism for somatogenic activity dependent on the coexistence of both GH and PRL receptors in the same cells. Another mechanism for specific placental endocrine activity is silencing of the alleles through genetic imprinting. Disruption of genetic imprinting of placental genes has been proposed as one of the explanations for the loss of cloned fetuses generated by somatic cell nuclear transfer.


Subject(s)
Embryonic and Fetal Development , Placental Hormones/physiology , Placentation , Animals , Cattle , Evolution, Molecular , Female , Gene Expression Regulation , Genomic Imprinting , Goats , Growth Hormone/genetics , Growth Hormone/physiology , Humans , Placental Lactogen/genetics , Placental Lactogen/physiology , Pregnancy , Prolactin/physiology , Receptors, Prolactin/physiology , Receptors, Somatotropin/physiology , Sheep
SELECTION OF CITATIONS
SEARCH DETAIL
...